<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094067</url>
  </required_header>
  <id_info>
    <org_study_id>AC-051-207</org_study_id>
    <nct_id>NCT01094067</nct_id>
  </id_info>
  <brief_title>Tezosentan in Patients With Pulmonary Arterial Hypertension</brief_title>
  <official_title>Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Demonstrate That a Single Infusion of Tezosentan Has Minimal Effect on Blood Pressure in Patients With Pulmonary Arterial Hypertension, Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or a Combination of Both.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, double-blind, randomized, placebo-controlled, cross-over study to demonstrate
      that a single infusion of tezosentan has minimal effect on blood pressure in patients with
      pulmonary arterial hypertension, treated with endothelin receptor antagonists,
      phosphodiesterase-5 inhibitors or a combination of both.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to slow recruitment, the study was prematurely discontinued.
  </why_stopped>
  <start_date>September 1, 2010</start_date>
  <completion_date type="Actual">September 1, 2011</completion_date>
  <primary_completion_date type="Actual">December 1, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in supine SBP from Baseline to 30 minutes at each visit (Visit 1 and Visit 2) - in mmHg</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in heart rate from Baseline to 30 minutes at each visit (Visit 1 and Visit 2) - in bpm</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo at visit 1, tezosentan at visit 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tezosentan at visit 1, placebo at visit 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-050089</intervention_name>
    <description>5 mg/h intravenously, Tezosentan</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          1. Signed informed consent prior to initiation of any study-mandated procedure

          2. Male and female patients 18 years of age or older

          3. Patients with PAH according to one of the following subgroups of the Dana Point
             Classification Group 1:

               -  Idiopathic, or

               -  Heritable, or

               -  Associated with connective tissue disease

          4. Documented hemodynamic diagnosis of PAH by right heart catheterization (not part of
             study mandated procedures):

               -  Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and

               -  Resting mean pulmonary vascular resistance (PVR) ≥ 240 dyn•s•cm 5 and

               -  Pulmonary capillary wedge pressure ≤ 15 mmHg

          5. Modified NYHA functional class II-III

          6. Patients on treatment with ERAs, PDE-5 inhibitors or a combination of both, if used
             for at least 3 months prior to Visit 1 and dosing kept stable for at least 28 days
             prior to Visit 1.

        Exclusion Criteria :

          1. Patients with PAH in Dana Point Classification Groups 2-5, and PAH Group 1 subgroups
             not covered by inclusion criterion No. 3

          2. Patients with sitting SBP &lt; 100 mmHg

          3. Patients with sitting DBP &lt; 60 mmHg

          4. Patients with body weight &lt; 50 kg (110 lbs)

          5. Patients with clinically significantly elevated liver enzymes (AST, ALT and/or
             alkaline phosphatase &gt; 3 times upper limit)

          6. Patients with clinically significant chronic renal insufficiency (serum creatinine
             &gt;2.5mg/dL / 221 µmol/L)

          7. Patients with moderate or severe hepatic impairment (Child-Pugh B and C)

          8. Patients who have received prostacyclin (epoprostenol) or prostacyclin analogs (e.g.,
             treprostinil, iloprost and beraprost) within 28 days of Visit 1

          9. Patients who have received any investigational drugs within 28 days of Visit 1

         10. Patients who have received cyclosporine A (CsA) or tacrolimus within 28 days of Visit
             1

         11. Psychotic, addictive or other disorder limiting the ability to provide informed
             consent or to comply with the study

         12. Life expectancy less than 12 months

         13. Females who are lactating or pregnant (positive pre-treatment pregnancy tests) (serum
             test at Screening and urine test on Visit 1 and 2) or females who are not using a
             reliable method of birth control (failure rate less than 1% per year) during the study
             and for at least one month after last administration of study drug

         14. Known hypersensitivity to any of the excipients of the drug formulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Antoine Beclere</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinjjyuku-ku, Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita, Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cardiovascular Center</name>
      <address>
        <city>Suita, Osaka</city>
        <zip>565-8865</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <disposition_first_submitted>July 13, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 13, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 23, 2012</disposition_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endothelin Receptor Antagonists</mesh_term>
    <mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
    <mesh_term>Tezosentan</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

